The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FDA breakthrough therapy designation of oncology products: The first-year experience.
Yangmin M. Ning
No relevant relationships to disclose
Tamy Kim
No relevant relationships to disclose
Virginia Ellen Maher
No relevant relationships to disclose
Amna Ibrahim
No relevant relationships to disclose
Anthony J. Murgo
No relevant relationships to disclose
Ann T. Farrell
No relevant relationships to disclose
Patricia Keegan
No relevant relationships to disclose
Robert L. Justice
No relevant relationships to disclose
Richard Pazdur
No relevant relationships to disclose